Last reviewed · How we verify
NCT05104229: SAVES-IBD
SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery
Phase 3 trial testing Aspirin 81Mg Ec Tab in Crohn Disease. Withdrawn.
31 May 2025
Quick facts
| Lead sponsor | Stefan Holubar MD MS FACS, FASCRS |
|---|---|
| Phase | Phase 3 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Start date | 1 June 2024 |
| Primary completion | 31 May 2025 |
| Estimated completion | 1 January 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Aspirin 81Mg Ec Tab — full drug profile →
- Standard of Care
Conditions studied
- Crohn Disease — all drugs for Crohn Disease →
- Ulcerative Colitis — all drugs for Ulcerative Colitis →
- Venous Thromboembolism — all drugs for Venous Thromboembolism →
Sponsor
Stefan Holubar MD MS FACS, FASCRS
Who can join
Adults 18 to 100, any sex, with Crohn Disease or Ulcerative Colitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Aim to determine if aspirin 81 mg orally twice daily is effective and safe as an extended VTE chemoprophylaxis agent after major abdominal surgery for IBD patients. Study will perform an open label trial of aspirin for VTE prophylaxis compared standard of care.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05104229
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Aspirin 81Mg Ec Tab
Trials testing the same drug.
- NCT06228820 — Aspirin Resistance in Trinidad. · Phase 2 · completed
- NCT05889468 — Postpartum ASA and NT-proBNP · Phase 4 · completed
- NCT05514847 — Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients · Phase 4 · active not recruiting
- NCT05009862 — The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Dis · Phase 4 · completed
- NCT04872283 — Effect of Postoperative Ketorolac on Bone Healing After Joint Fusion · Phase 3 · unknown
Other recruiting trials for Crohn Disease
Currently open trials in the same condition.
- NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
- NCT07310095 — A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) · Phase 4 · recruiting
- NCT07364734 — Epidemiological Characteristics and Efficacy Evaluation of Difficult-To-Treat Crohn's Disease · recruiting
- NCT07170462 — Cranberry and Gut Health in Crohn's Disease · EARLY_PHASE1 · recruiting
- NCT07196722 — A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05104229 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stefan Holubar MD MS FACS, FASCRS
- Last refreshed: 18 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05104229.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing